positive
1h agoAstraZeneca Q3 revenue climbs 10 % as drug‑sales momentum holds
AstraZeneca beat expectations in Q3 2025 with core earnings at US $2.38 per share (+12 % YoY) and revenue of US $15.19 billion (+10%).
Strong performance from its cancer, cardiovascular and kidney‑disease treatment portfolios helped maintain full‑year guidance of high single‑digit revenue growth and low double‑digit EPS growth.
The company reiterated ambitions for US $80 billion in annual sales by 2030, pointing to its U.S. listing plans and investments in local manufacturing as part of global expansion strategy.
Reuters• By Sneha Pathak
Explore:High Return Equity Mutual Fund
positive
1h agoAstraZeneca Q3 revenue climbs 10 % as drug‑sales momentum holds
AstraZeneca beat expectations in Q3 2025 with core earnings at US $2.38 per share (+12 % YoY) and revenue of US $15.19 billion (+10%).
Strong performance from its cancer, cardiovascular and kidney‑disease treatment portfolios helped maintain full‑year guidance of high single‑digit revenue growth and low double‑digit EPS growth.
The company reiterated ambitions for US $80 billion in annual sales by 2030, pointing to its U.S. listing plans and investments in local manufacturing as part of global expansion strategy.
Reuters• By Sneha Pathak
Explore:High Return Equity Mutual Fund
Breaking
positive
AstraZeneca Q3 revenue climbs 10 % as drug‑sales momentum holds
about 2 hours ago
1 min read
76 words
AstraZeneca beats Q3 targets, sustains growth and reiterates US$80 bn sales goal by 2030.
AstraZeneca beat expectations in Q3 2025 with core earnings at US $2.38 per share (+12 % YoY) and revenue of US $15.19 billion (+10%).
Strong performance from its cancer, cardiovascular and kidney‑disease treatment portfolios helped maintain full‑year guidance of high single‑digit revenue growth and low double‑digit EPS growth.
The company reiterated ambitions for US $80 billion in annual sales by 2030, pointing to its U.S. listing plans and investments in local manufacturing as part of global expansion strategy.
AstraZeneca beat expectations in Q3 2025 with core earnings at US $2.38 per share (+12 % YoY) and revenue of US $15.19 billion (+10%).
Strong performance from its cancer, cardiovascular and kidney‑disease treatment portfolios helped maintain full‑year guidance of high single‑digit revenue growth and low double‑digit EPS growth.
The company reiterated ambitions for US $80 billion in annual sales by 2030, pointing to its U.S. listing plans and investments in local manufacturing as part of global expansion strategy.
Companies:
AstraZeneca
Tags:
stocks
global
stocks
global
AstraZeneca
pharma
earnings
Nov 8, 2025 • 22:10 IST